Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, published a new report today that highlights the significant clinical and commercial potential of peptide-binding G-protein- coupled receptors (GPCRs) in treating metabolic, central nervous system, immune and inflammatory, gastrointestinal, and genitourinary diseases and disorders. The report, entitled GPCR Modulators: Emerging Therapeutic Opportunities, also finds that Amylin Pharmaceuticals' work with peptide- binding GPCR modulators will result in an agent that could significantly benefit the obesity population.
"Recent studies conducted in humans suggest that PYY has significant potential as an appetite suppressant and, therefore, as a treatment for obesity," said Sylvia Marecki, Ph.D., analyst at Decision Resources. "Based on these findings, we anticipate that PYY receptor modulators, such as Amylin's AC-162352 (PYY3-36), will be among the first peptide-binding GPCR modulators to reach the obesity market and will benefit a significant proportion of the obese patient population."
The report also includes the views of leading academic experts in the field of GPCRs. Experts interviewed agree that despite the number of successful drugs that target GPCRs, the basic biology of GPCRs remains poorly understood. A clearer understanding of structure-function relationships, conformational changes, and factors regulating the association of a given GPCR with intracellular proteins would greatly improve drug discovery and development efforts.
GPCR Modulators: Emerging Therapeutic Opportunities is produced by Decision Resources in association with Nature Reviews Drug Discovery. Decision Resources provides an analysis of the business landscape and market opportunities in relevant disease indications, while Nature Reviews Drug Discovery provides the views of leading authorities on a number of issues of fundamental importance to GPCR research. The report features 18 interviews conducted by Nature Reviews Drug Discovery with leading academic experts on the subject of GPCRs, providing timely insight into the directions of GPCR research and how this research will impact drug discovery and development in the future.
About the Report
GPCR Modulators: Emerging Therapeutic Opportunities is a special Pathways and Processes report benefiting from the partnership between Decision Resources and Nature Reviews Drug Discovery. Published by Decision Resources, the Pathways and Processes series focuses on cellular and molecular pathways, providing insight into cutting-edge developments relating to drug targets with the potential to significantly change treatment practice and impact multiple pharmaceutical markets. Comments from leading academic GPCR investigators interviewed by Nature Reviews Drug Discovery are integrated into the report, thereby providing exclusive insights into the potential scientific and business opportunities for the next generation of targeted therapies.
About Nature Reviews Drug Discovery
Nature Reviews Drug Discovery is a monthly review journal that publishes authoritative, peer-reviewed articles by leaders in the field--providing a complete overview of the drug discovery and development arena, from disease mechanisms and chemistry to clinical development and regulatory issues. The journal, which integrates academia and industry, features cutting-edge review articles and highlights of the latest primary papers, as well as opinion articles and historical perspectives. For more information, visit www.nature.com/reviews/drugdisc.
About Decision Resources
Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen therapeutic markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/